CORD-19:038354e8830fe01feb621a12e8a8c467a15b6354 / 158609-159018 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T992","span":{"begin":0,"end":409},"obj":"Sentence"},{"id":"T81455","span":{"begin":0,"end":409},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Janssen's R170591, a topically applied compound with a reported EC 50 against RSV of \u003c1 nM, is in preclinical study; Bristol-Myers Squibb's BMS-433771, an orally bioavailable compound with a reported EC 50 against RSV of 10 nM, is in preclinical study; and ViroPharma's VP14637, a compound delivered by small particle aerosol (SPA) inhalation with an EC 50 against RSV of \u003c1 nM, is completing phase 1 studies."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T60","span":{"begin":0,"end":409},"obj":"Sentence"}],"text":"Janssen's R170591, a topically applied compound with a reported EC 50 against RSV of \u003c1 nM, is in preclinical study; Bristol-Myers Squibb's BMS-433771, an orally bioavailable compound with a reported EC 50 against RSV of 10 nM, is in preclinical study; and ViroPharma's VP14637, a compound delivered by small particle aerosol (SPA) inhalation with an EC 50 against RSV of \u003c1 nM, is completing phase 1 studies."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T847","span":{"begin":140,"end":143},"obj":"Disease"}],"attributes":[{"id":"A847","pred":"mondo_id","subj":"T847","obj":"http://purl.obolibrary.org/obo/MONDO_0006687"}],"text":"Janssen's R170591, a topically applied compound with a reported EC 50 against RSV of \u003c1 nM, is in preclinical study; Bristol-Myers Squibb's BMS-433771, an orally bioavailable compound with a reported EC 50 against RSV of 10 nM, is in preclinical study; and ViroPharma's VP14637, a compound delivered by small particle aerosol (SPA) inhalation with an EC 50 against RSV of \u003c1 nM, is completing phase 1 studies."}